article thumbnail

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

BioPharma Reporter

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

article thumbnail

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds April 14, 2023: RECOVER in Action – Status of Clinical Trial Protocols (Kanecia Zimmerman, PhD, MD, MPH)

Rethinking Clinical Trials

There are many hypothesized causes that may co-exist in the same patient, such as persistent virus or antigens, reactivation of other viruses, uncontrolled immune responses, damage to a wide range of organs and tissues, and injury to blood vessels and abnormal blood clotting. It’s all over the place.

article thumbnail

Therini Bio raises funds to develop neurodegenerative disease therapies

Pharmaceutical Technology

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials.

article thumbnail

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

article thumbnail

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Scienmag

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

article thumbnail

Clinical Trials for Celiac Disease: Insights from Beyond Celiac’s Kate Avery

XTalks

However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. Some of the approaches being studied include: Enzyme therapy: Researchers are testing enzymes that may help break down gluten in the digestive system, reducing the risk of immune system activation and damage to the small intestine.